|
|
Article: Manufacture of Actiq transferred to Salt Lake City facility.
- Article from:
- Biotech Week
- Article date:
- April 30, 2003
CopyrightCOPYRIGHT 2003 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
2003 APR 30 - (NewsRx.com & NewsRx.net) -- Cephalon, Inc., (CEPH) announced that manufacture of Actiq (oral transmucosal fentanyl citrate) [C-II] for the U.S. market has been transferred from a contract manufacturer to Cephalon's recently expanded facility in Salt Lake City, Utah.
The move follows the February 19, 2003, approval by the U.S. Food and Drug Administration (FDA) of a new compressed powder formulation of Actiq for the management of breakthrough pain in cancer patients who are tolerant to opioid therapy. This formulation, which the Salt Lake City facility has manufactured for the European market since November 2000, replaces the current sugar melt ...